Travere Therapeutics, Inc. (TVTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$50.27

From 52W high−22.36%

Volume3.56M

Market cap$5.03B

P/E (TTM)—

P/S (TTM)7.7x

Div yield—

Key dataNov 4, 2026

Open

$50.27

From 52W high

−22.36%

Volume

3.56M

Market cap

$5.03B

ValuationView details →

P/E (Fwd)

18.4x

EV/EBITDA

−52.8x

P/E (TTM)

—

RSI (14)

47.6

MomentumView details →

1D Return

+6.09%

YTD Return

+37.44%

SummaryUpdated Sep 1, 2026

Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company founded in 2008 and headquartered in San Diego, California. Originally incorporated as Retrophin, Inc., the company rebranded to Travere Therapeutics in November 2020. The company specializes in developing and commercializing therapies for rare diseases, with a particular focus on rare kidney disorders and metabolic conditions. Travere has successfully transitioned from a development-stage company to a commercial-stage biopharmaceutical enterprise, with multiple approved products generating revenue and a robust pipeline of investigational therapies targeting significant unmet medical needs in rare disease populations.

Ask drillr about Travere Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

18.4x

P/E (TTM)

—

EV/EBITDA

−52.8x

EV/Sales

8.0x

P/S (TTM)

7.7x

P/B (TTM)

222.8x

ProfitabilityView details →

Gross Margin

94.72%

Net Margin

−18.66%

EBITDA Margin

−15.06%

ROE (TTM)

−538.02%

ROA (TTM)

−14.32%

Asset Turnover

0.79x

GrowthView details →

Revenue YoY

+49.38%

EPS YoY

−48.57%

FCF YoY

+268.73%

Revenue CAGR 3Y

+64.89%

EPS CAGR 3Y

+86.27%

EBITDA YoY

—

MomentumView details →

1D Return

+6.09%

YTD Return

+37.44%

1Y Return

+55.74%

RSI (14)

47.6

vs 50D SMA

−9.65%

vs 200D SMA

+11.85%

Capital & dividendView details →

Debt/Equity

27.28x

Current Ratio

3.00x

Quick Ratio

2.95x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.55

EPS Surprise

−891.88%

Beats (12Q)

4/12

Next Q EPS Est

$0.47

Avg Surprise (4Q)

−274.17%

Rev Surprise

14.99%

Financials snapshotView financials →

Revenue (TTM)

651.03M

Net Income (TTM)

−121.51M

Op. CF (TTM)

176.59M

Next earningsFeb 18, 2027 →

Latest newsMore news →

Travere Therapeutics, Inc. reported a quarterly loss of $0.55 per share, compared with a loss of $0.25 per share expected and earnings of $0.28 per share a year earlier.2d ago

Travere Therapeutics, Inc. reported third-quarter 2026 financial results and said FILSPARI net product sales were $200 million for the quarter.2d ago

Similar companies

CRISPR Therapeutics AGCRSP Lepu Biopharma Co., Ltd.02157.HK Erasca, Inc.ERAS CK Life Sciences Int'l., (Holdings) Inc.00775.HK Apellis Pharmaceuticals, Inc.APLS Dianthus Therapeutics, Inc.DNTH Find similar companies →

Latest newsMore news →

Travere Therapeutics, Inc. reported a quarterly loss of $0.55 per share, compared with a loss of $0.25 per share expected and earnings of $0.28 per share a year earlier.2d ago Travere Therapeutics, Inc. reported third-quarter 2026 financial results and said FILSPARI net product sales were $200 million for the quarter.2d ago Travere Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, after U.S. markets close, and host a conference call and webcast at 4:30 p.m. ET.9d ago